A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study Of Risankizumab Compared To Ustekinumab For The Treatment Of Adult Subjects With Moderate To Severe Crohn's Disease Who Have Failed Anti-Tnf Therapy
Posted Date: Sep 21, 2021
- Investigator: Loren Brook
- Type of Study: Drug
This study will compare the efficacy and safety of risankizumab versus ustekinumab for the treatment of adult subjects with moderate to severe Crohn's disease (CD) who have failed anti-TNF therapy.
Age 18-80. Diagnosis Of Crohn's Disease For At Least 3 Months Prior To Screening. Willing And Able To Comply With Procedures Required In The Protocol.
Crohn's Disease, Crohn's
For More Information: